Background And Aims: Enhanced recovery after cesarean (ERAC) is an interdisciplinary approach to improve patient outcomes following cesarean section. ERAC's execution must be constantly evaluated. Thus, we aimed to analyze parameters associated with ERAC adoption for clinical care in this expanded systematic review.
Material And Methods: A systematic literature search using Epistemonikos, Google Scholar, PubMed, and Scopus was done until February 2023. The appropriate observational and experimental research comparing the effects of ERAC protocols with conventional care on postoperative adverse events, operation-related characteristics, time to first (oral intake, mobilization, bowel movement, and urinary catheter removal), and opioid use. Meta-analyses were conducted using the RevMan 5.4.1. and Comprehensive Meta-Analysis version 3.3 software.
Results: In total, 23 studies were included in this systematic review. ERAC implementation was found to be associated with improvement in terms of shorter postoperative hospital stays and faster time to first liquid intake, first solid diet, urinary catheter removal, and mobilization. Furthermore, the rate of opioid-free treatment, total in-hospital morphine milligram equivalent (MME), daily in-hospital MME, and total prescribed opioid pills at discharge (all parameters, < 0.01) were significantly better in the ERAC group than in the conventional care group. However, no significant difference was observed regarding postoperative adverse events, blood loss, operation duration, and total prescribed MME at discharge parameters between the two observed groups.
Conclusion: ERAC implementation is associated with better healthcare delivery, as determined by shorter time to first, lower opioid consumption, and shorter postoperative length of stay compared with conventional care. However, it is not associated with a lower dosage of opioid prescription at discharge.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867361 | PMC |
| http://dx.doi.org/10.4103/joacp.joacp_339_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AI-driven Personalized Medicine: Transforming Clinical Practice in Inflammatory Bowel Disease.
Gastroenterology
March 2025
APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
Inflammatory bowel disease (IBD) is marked by significant clinical heterogeneity, posing challenges for accurate diagnosis and personalized treatment strategies. Conventional approaches, such as endoscopy and histology, often fail to adequately and accurately predict medium and long-term outcomes, leading to suboptimal patient management. Artificial intelligence (AI) is emerging as a transformative force enabling standardized, accurate, and timely disease assessment and outcome prediction, including therapeutic response.
View Article and Find Full Text PDFIndividualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.
J Infus Nurs
March 2025
Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.
View Article and Find Full Text PDFA hands-free wearable electrolarynx for communication in tracheostomized mechanically ventilated critically ill patients: a case series.
J Anesth
March 2025
Intensive Care Unit, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
The electrolarynx facilitates communication for tracheostomized mechanically ventilated patients. However, its effectiveness is often constrained by patient weakness. A hands-free electrolarynx offers a potential solution, enabling speech without the need to hold the device.
View Article and Find Full Text PDFNovel, multimodal, simulation practice with evolving case scenario for teaching familial communications in undergraduate medical training.
Med Teach
March 2025
Centre for Healthcare Simulation, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
There is a growing recognition of the importance of familial involvement in patient care. In Asian societies, communications with patients' families for routine medical updates and shared decision-making are considered part-and-parcel of clinical practice. Yet, training in familial communications has remained, by and far, a neglected aspect of conventional communications skills training in the medical curriculum, despite distinctive nuances in the communications approach.
View Article and Find Full Text PDFLifetime classic psychedelic use and headaches: A cross-sectional study.
J Psychopharmacol
March 2025
Department of Neuroscience, Centre for Cluster Headache, Karolinska Institutet, Stockholm, Sweden.
Background: Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin are potentially promising new treatment candidates for these conditions.
Aims: The aim of the present study was to investigate the possible relationship between the lifetime use of classic psychedelics and frequent bad headaches in a large British cohort sample.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!